Traditionally, protein and antibody engineers source DNA fragments from third-party gene synthesis companies who use chemically synthesized oligos as a starting point. This legacy service is prone to long delays when sequences are complex or when oligo supply chains are slow. The negative effect on the productivity of high-throughput screening labs in turn slows down drug development and research timelines. DNA Script (SLAS Europe 2023 in Brussels, Booth #233) developed an automated oligo synthesis benchtop platform powered by enzymatic DNA synthesis, that can produce oligos for gene assembly in a matter of hours and within the confines of your lab. With oligos in hand, researchers can assemble genes of 1-2 kb in a single day. This means that the timeline from design to sequence-verified double-stranded DNA fragment can be reduced down to just 3 days. With more control over the supply of DNA oligos, antibody and protein engineering labs can ensure consistent productivity and accelerate the iterative design-build-test cycles that are keystones to the innovations developed in a high-throughput engineering lab.
